Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Palbociclib and Binimetinib in RAS-Mutant Cancers: A ComboMATCH Treatment Trial

NCT05554367 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT05554367
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05554367 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Palbociclib and Binimetinib in RAS-Mutant Cancers: A ComboMATCH Treatment Trial
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 13, 2023
Completion date
August 26, 2028
Enrollment
199 (estimated)
Sites
265

Conditions

As the registry lists them; a condition with its own page is linked.

exocrine pancreas carcinoma, malignant solid neoplasm, ovarian low grade serous adenocarcinoma, stage iv ovarian cancer ajcc v8, stage iv pancreatic cancer ajcc v8